Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity
Oncology Reports · 2025
DOI: 10.3892/or.2025.8988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2025. Verfasst von Makoto Nakayama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Core Research Laboratories, Bio‑Pharmaceutical Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Receptors, TNF-Related Apoptosis-Inducing Ligand, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Core Research Laboratories, Bio‑Pharmaceutical Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan.
- Project and Product Management Group 3, CMC Development, Manufacturing, Kyowa Kirin Co., Ltd., Tokyo 100‑0004, Japan.
- Global Operational Transformation Kyowa Kirin International Plc., Marlow SL7 1HZ, UK.
- Innovation Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan.
Zitieren
APA
Nakayama, M., Takagi-Maeda, S., Machino, Y., Nihira, K., Inoue, M., Takahashi, N., & Usami, K. (2025). Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. Oncology Reports. https://doi.org/10.3892/or.2025.8988
Vancouver
Nakayama M, Takagi-Maeda S, Machino Y, Nihira K, Inoue M, Takahashi N, et al. Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. Oncology Reports. 2025. doi:10.3892/or.2025.8988
BibTeX
@article{Nakayama2025,
author = {Nakayama, Makoto and Takagi-Maeda, Sayaka and Machino, Yusuke and Nihira, Kaito and Inoue, Miho and Takahashi, Nobuaki and Usami, Katsuaki},
title = {Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity},
journal = {Oncology Reports},
year = {2025},
doi = {10.3892/or.2025.8988}
}
EUVIMED